甲胺通过减少de-novo pyrimidine合成来克服对低甲基化剂的耐药性
Bianca Rivera-Peña1, Samarpana Chakraborty1, Yang Shi2
1Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, USA.
甲胺克服了在骨髓分裂综合征 (MDS) 中对DNA低甲基化剂 (HMA) 的耐药性. 这种抗叶酸类药物抑制了皮里米丁合成,恢复了对HMA和venetoclax的敏感性,并促进了干细胞的分化.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 像5-azacitidine和decitabine这样的DNA低甲基化剂 (HMA) 是标准的MDS治疗方法.
- 治疗耐药性通常涉及增加de-novo胺合成,与HMA疗效竞争.
- 抑制皮里米丁合成可以恢复抗性白血病的敏感性.
研究的目的:
- 研究PYR作为一种克服MDS中HMA耐药性的策略.
- 评估PYR对白血病细胞亡,分化和pyrimidine合成的影响.
- 在HMA和Ven耐药模型中评估PYR与venetoclax (Ven) 的协同作用.
主要方法:
- 在各种白血病细胞系中测试PYR诱导的亡.
- 在抗性细胞系和小鼠模型中评估PYR与Ven和HMA结合的效果.
- 在初级MDS样本中评估PYR对干细胞和祖细胞分化的影响.
主要成果:
- 在白血病细胞系中,PYR诱导了亡,并与Ven.表现出协同作用.
- 在耐药模型中,PYR证明了与HMAs的添加效应.
- 在MDS样本中,PYR直接抑制了新的pyrimidine合成,并促进了干细胞/原始细胞的分化.
结论:
- 皮瑞是通过抑制皮里米丁合成来克服MDS中HMA耐药性的有前途的药物.
- PYR和Ven的组合显示出治疗HMA和Ven抗性白血病的潜力.
- PYR恢复灵敏度和促进分化的能力提供了一个临床可行的策略.
更多相关视频
07:34Quantitative Determination of De Novo Fatty Acid Synthesis in Brown Adipose Tissue Using Deuterium Oxide
Published on: May 12, 2023
08:38Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis EAE Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge
Published on: April 9, 2012
相关概念视频
Redox Titration: Other Oxidizing and Reducing Agents
Synthesis and Decomposition Reactions
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Dehydration Synthesis
Dehydration synthesis (also called a condensation reaction) is the chemical process in which two molecules covalently link together to form a new molecule, along with the release of a water molecule. Many physiologically important compounds form by dehydration synthesis reactions, such as complex carbohydrates, proteins, DNA, and RNA.
Synthesis of carbohydrates
Sugar molecules are covalently linked together by dehydration synthesis. During the reaction, the hydroxyl (-OH) group from...
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Resistivity
